147849-63-6

Basic information

• Product Name: (5R)-5-Hydroxy-3-oxo-6-(benzyloxy)-hexanoic Acid tert-Butyl Ester
• Synonyms: (5R)-5-Hydroxy-3-oxo-6-(benzyloxy)-hexanoic Acid tert-Butyl Ester;VBXDDEFKXNFJLL-OAHLLOKOSA-N
• CAS NO: 147849-63-6
• Molecular Formula: C₁₇H₂₄O₅
• Molecular Weight: 308.36946
• Product Categories: Aromatics, Chiral Reagents, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 147849-63-6.mol

Chemical Properties

• Appearance: /
• Solubility: Dichloromethane, Ethyl Acetate
• CAS DataBase Reference: (5R)-5-Hydroxy-3-oxo-6-(benzyloxy)-hexanoic Acid tert-Butyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: (5R)-5-Hydroxy-3-oxo-6-(benzyloxy)-hexanoic Acid tert-Butyl Ester(147849-63-6)
• EPA Substance Registry System: (5R)-5-Hydroxy-3-oxo-6-(benzyloxy)-hexanoic Acid tert-Butyl Ester(147849-63-6)

Safety Data

• Hazardous Substances Data: 147849-63-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(5R)-5-Hydroxy-3-oxo-6-(benzyloxy)-hexanoic Acid tert-Butyl Ester is used as an intermediate compound for the synthesis of various antifungal macrolide antibiotics. Its unique structure allows it to be a key component in the development of these drugs, which are essential for treating fungal infections.
Used in the Preparation of (+)-Roxaticin:
(5R)-5-Hydroxy-3-oxo-6-(benzyloxy)-hexanoic Acid tert-Butyl Ester is used as a precursor in the synthesis of (+)-Roxaticin, an antifungal macrolide antibiotic. (5R)-5-Hydroxy-3-oxo-6-(benzyloxy)-hexanoic Acid tert-Butyl Ester plays a crucial role in the development of this antibiotic, which is effective against a range of fungal infections.
Used in the Preparation of Phorboxazole B:
(5R)-5-Hydroxy-3-oxo-6-(benzyloxy)-hexanoic Acid tert-Butyl Ester is also used in the preparation of Phorboxazole B, another antifungal macrolide antibiotic. Its presence in the synthesis process is vital for the production of this drug, which has potential applications in treating various fungal infections.
Used in the Preparation of Bryostatin 2:
(5R)-5-Hydroxy-3-oxo-6-(benzyloxy)-hexanoic Acid tert-Butyl Ester is utilized in the synthesis of Bryostatin 2, a complex macrolide compound with potential antifungal and anti-cancer properties. (5R)-5-Hydroxy-3-oxo-6-(benzyloxy)-hexanoic Acid tert-Butyl Ester serves as an essential building block in the creation of Bryostatin 2, which is currently under investigation for its therapeutic potential.

Upstream product

• 540-88-5 acetic acid tert-butyl ester 
• 114784-19-9 (R)-Methyl 4-benzyloxy-3-hydroxybutanoate 
• 147849-60-3 Methyl (S)-4-(benzyloxy)-3-hydroxybutanoate 
• 60656-87-3 benzyloxyacetoaldehyde 
• 146431-18-7 (Z)-1,3-bis(trimethylsiloxy)-1-tert-butoxybuta-1,3-diene 
• 106058-91-7 (+)-(R)-ethyl 4-benzyloxy-3-hydroxybutanoate 
• 32122-09-1 ethyl benzyloxyacetate 
• 95967-46-7 tert-Butyl 4-benzyloxy-3-oxobutanoate 
• 147849-58-9 tert-Butyl (R)-4-benzyloxy-3-hydroxybutanoate 
• 147849-59-0 tert-Butyl (S)-4-benzyloxy-3-hydroxybutanoate 

Downstream Products

• 215876-09-8 (3R,5R)-6-benzyloxy-3,5-dihydroxy-hexanoic acid tert-butyl ester 
• 549502-23-0 (3S,5R)-6-benzyloxy-3,5-dihydroxy-hexanoic acid tert-butyl ester 
• 296785-14-3 (6R)-4-methoxy-6-(benzyloxymethyl)-5,6-dihydro-2H-pyran-2-one 
• 296795-16-9 (9R)-9-(benzyloxymethyl)-1,4,8-trioxaspiro[4.5]decane-7-one 
• 296795-40-9 (9R)-9-(benzyloxymethyl)-1,4,8-trioxaspiro[4.5]decan-7-ol 
• 310883-88-6 (2R,4R,6R)-2-[4-((E)-2-[(2R,3S,4S,5S,6R)-3,5-dimethyl-6-[2-(trimethylsilyloxyethyl)]-4-(triphenylsilyloxy)-tetrahydro-2H-pyran-2-yl]prop-1-enyl)(1,3-oxazol-2-yl)]-methyl-4-methoxy-2-(triethylsilyloxy)-6-(triethylsilyloxymethyl)-tetrahydro-2H-pyran-2-ol 
• 215876-23-6 C₇₇H₁₂₉NO₁₂Si₄ 
• 215876-22-5 C₇₁H₁₁₅NO₁₂Si₃ 
• 247146-64-1 C₅₄H₉₂O₁₁SSi₃ 
• 215876-21-4 trifluoro-methanesulfonic acid 4-(tert-butyl-dimethyl-silanyloxy)-6-(3-{6-[2-(tert-butyl-dimethyl-silanyloxy)-3-(4-methoxy-benzyloxy)-butyl]-5,6-dihydro-4H-pyran-2-yl}-3-methyl-but-1-enyl)-tetrahydro-pyran-2-ylmethyl ester 
• 215876-20-3 6-{3-[4-(tert-butyl-dimethyl-silanyloxy)-6-(tert-butyl-dimethyl-silanyloxymethyl)-tetrahydro-pyran-2-yl]-1,1-dimethyl-allyl}-2-[2-(tert-butyl-dimethyl-silanyloxy)-3-(4-methoxy-benzyloxy)-butyl]-3,4-dihydro-2H-pyran 
• 247146-85-6 [(2S,4R,6R)-4-(tert-Butyl-dimethyl-silanyloxy)-6-((E)-3-{(S)-6-[(2R,3R)-2-(tert-butyl-dimethyl-silanyloxy)-3-(4-methoxy-benzyloxy)-butyl]-5,6-dihydro-4H-pyran-2-yl}-3-methyl-but-1-enyl)-tetrahydro-pyran-2-yl]-methanol 
• 247146-46-9 2-benzyloxymethyl-4-(tert-butyl-dimethyl-silanyloxy)-6-(tert-butyl-dimethyl-silanyloxymethyl)-tetrahydro-pyran 
• 215876-11-2 (2R,4S,6S)-2-Benzyloxymethyl-6-hydroxymethyl-tetrahydro-pyran-4-ol 

Relevant articles and documents

Diastereoselective synthesis of syn-3,5-dihydroxyesters via ruthenium-catalyzed asymmetric transfer hydrogenation

The asymmetric transfer hydrogenation of chiral 5-hydroxy-3-ketoesters in 2-propanol using chlororuthenium(II)arene/β-amino alcohol in situ catalyst combinations or a pre-synthesized Ru-{β-amino alcohol} true catalyst, provides syn-3,5-dihydroxyesters in

Enantioselective synthesis of oasomycin A, part II: Synthesis of the C29-C46 subunit

(Chemical Equation Presented) Putting the pieces together: The total synthesis of the natural macrolide oasomycin A has been realized. Key fragment couplings include an anti-Felkin selective aldol addition (green), Kociensky-Julia olefinations (red), and

Synthesis of ethyl and t-butyl (3R,5S)-dihydroxy-6-benzyloxy hexanoates via diastereo- and enantioselective microbial reduction

Previously we have demonstrated the reduction of ethyl diketoester 4 to the corresponding dihydroxy ester 6a by Acinetobacter sp. SC13874. Recently we screened more than 100 cultures for microbial reduction of both the ethyl and t-butyl diketoesters 4 and

Asymmetric synthesis of bryostatin 2

The potent bryostatin antitumor agents are currently in phase II clinical trials for the treatment of a variety of forms of cancer. Aldol reactions and directed reductions are among the essential steps for the formation of fragments A-C in the total synthesis of the title compound. Coupling of these fragments by sulfone-based olefination and alkylation reactions was followed by macrocyclization and introduction of the enoate moieties on rings B and C.

Asymmetric Hydrogenation of 3,5-Dioxoesters Catalyzed by Ru-binap Complex: A Short Step Asymmetric Synthesis of 6-Substituted 5,6-dihydro-2-pyrones

Asymmetric hydrogenation of 3,5-dioxoesters 1a-c using Ru2Cl4((R) or (S)-binap)2(NEt3) as the catalyst gave dominantly anti 3,5-dihydroxyesters 2, which were then converted into unsaturated lactones 5a-b (ca. 80percent e.e.).The pathway of the hydrogenation reaction was also investigated by asymmetric hydrogenation of (R)- or (S)-5-hydroxy-3-oxoesters 8a-c.It was revealed that the Ru-binap catalyzed hydrogenation of 1a-b proceed dominantly via the β-diketone mode.A convenient asymmetric synthesis of hydroxylactone 3c and unsaturated lactone 5c was presented.Key words: 3,5-dioxoester; Ru-binap catalyst; asymmetric hydrogenation; asymmetric synthesis; lactone